scholarly article | Q13442814 |
P356 | DOI | 10.1200/JCO.1998.16.11.3528 |
P698 | PubMed publication ID | 9817271 |
P2093 | author name string | M Green | |
S Bernard | |||
J E Herndon | |||
L Leone | |||
R W Carey | |||
S Seagren | |||
J Rosenman | |||
C T Chung | |||
N C Choi | |||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
lung cancer | Q47912 | ||
P304 | page(s) | 3528-3536 | |
P577 | publication date | 1998-11-01 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer | |
P478 | volume | 16 |
Q34671664 | A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer |
Q37293955 | A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. |
Q47557590 | Barriers to Combined-Modality Therapy for Limited-Stage Small-Cell Lung Cancer |
Q34501938 | Chemoradiation schedules--what radiotherapy? |
Q38155779 | Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. |
Q36051734 | Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer |
Q35543239 | Complex and controversial issues in locally advanced non‐small cell lung carcinoma |
Q41380574 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial |
Q54953051 | Current standards for clinical management of small cell lung cancer. |
Q34384459 | Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages). |
Q33413185 | Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer |
Q34727914 | Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer |
Q37694009 | Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer |
Q55093161 | Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer. |
Q35583915 | Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms |
Q35543182 | Limited‐disease small‐cell lung cancer |
Q35120111 | Lung cancer 5: state of the art radiotherapy for lung cancer |
Q34913450 | Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop |
Q79782954 | Mid-course thoracic radiotherapy with cisplatin-etoposide chemotherapy in limited-stage small-cell lung cancer |
Q35198443 | New approaches for small-cell lung cancer: local treatments |
Q94063981 | Once Daily High-dose Radiation (≥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer |
Q84495886 | Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes |
Q38732983 | Optimal Radiation Therapy for Small Cell Lung Cancer |
Q45255415 | Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma |
Q36041017 | Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. |
Q37242284 | Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. |
Q74017032 | Plasmid/liposome transfer of the human manganese superoxide dismutase transgene prevents ionizing irradiation-induced apoptosis in human esophagus organ explant culture |
Q36302195 | Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer |
Q33902741 | Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. |
Q37626969 | Progress in the management of limited-stage small cell lung cancer |
Q35687700 | Progress in the therapy of small cell lung cancer |
Q36526895 | Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with lim |
Q35576272 | Radiation Dose Intensification in Limited-Stage Small-Cell Lung Cancer |
Q35552410 | Radiation dose escalation in limited-stage small-cell lung cancer |
Q43886078 | Radiation therapy for small-cell lung cancer: results of the 1995-1997 patterns of care process survey in Japan |
Q33339670 | Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). |
Q35124160 | Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer |
Q36334696 | Simultaneous integrated dose reduction intensity-modulated radiotherapy applied to an elective nodal area of limited-stage small-cell lung cancer |
Q44676670 | Small cell carcinoma of the head and neck: report of three cases |
Q37937880 | Small cell lung cancer: new clinical recommendations and current status of biomarker assessment |
Q37772816 | Small cell lung cancer: past, present, and future |
Q78027906 | Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report |
Q34501946 | The treatment of limited small cell lung cancer: a report of the progress made and future prospects |
Q34384504 | Thoracic radiotherapy in the treatment of limited disease of small-cell cancer: sequence and fractionation |
Q37301691 | Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. |
Q41357983 | Treatment of limited disease small cell lung cancer: the multidisciplinary team |
Q53705076 | Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer? |
Q77956067 | [Accelerated hyperfractionated compared with conventional radiotherapy in limited small-cell lung carcinoma, with concurrent chemotherapy] |
Q73343084 | [What are the optimal thoracic radiotherapy modalities in limited small cell lung cancer? Review of recent clinical trials.] |
Search more.